Current and future treatment strategies for type 2 diabetes: The β-cell a therapeutic target

Current Opinion in Investigational Drugs

Volumn 2, Issue 11, 2001, Pages 1568-1574

  Tyrberg, B ^a   Levine, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cell; Exendin 4; Thiazolidinedione; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BIGUANIDE DERIVATIVE; CHROMIUM PICOLINATE; D 400; EPICATECHIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIRAGLUTIDE; METFORMIN; MOMORDICA CHARANTIA EXTRACT; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; RX 871024; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR; TOLBUTAMIDE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BLINDNESS; BLOOD GLUCOSE MONITORING; CARDIOTOXICITY; CELL GROWTH; CELL LOSS; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DIET THERAPY; DISEASE MODEL; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; LACTIC ACIDOSIS; LIFESTYLE; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS SURGERY; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; ISLETS OF LANGERHANS; SULFONYLUREA COMPOUNDS;

EID: 0035187543     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group
2. β-cell activity and destruction in type 1 diabetes
3. Pathophysiology and pharmacological treatment of insulin resistance
4. The prevalence of diabetes in a Swedish population of 280,411 inhabitants. A report from the Skaraborg Diabetes Registry
5. The Sardinian IDDM study: 1 Epidemiology and geographical distribution of IDDM in Sardinia during 1984 to 1994
6. Diabetes statistics
7. Diabetes complication
8. Costs of diabetes
9. Diet and exercise dramatically delay type 2 diabetes - Diabetes medication metformin also effective
10. The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work?
11. Electrical activity in pancreatic islet cells
12. Tolbutamide stimulation and inhibition of insulin release: Studies of the underlying ionic mechanisms in isolated rat islets
13. The sulphonylurea receptor may be an ATP-sensitive potassium channel
14. Electrophysiology of the pancreatic β-cell
15. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin
16. Dynamics of β-cell mass in the growing rat pancreas. Estimation with a simple mathematical model
17. Adaptation of islets of Langerhans to pregnancy: β-cell growth, enhanced insulin secretion and the role of lactogenic hormones
18. Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance
19. Diabetes: Statins, fibrates, or both?
20. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the β-cell function
21. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets
22. Accelaterated loss of islet β-cells in sucrose-fed Goto-Kakizaki rats, a genetic model of non-insulin-dependent diabetes mellitus
23. Amyloid and polypeptide hormones: What is their relationship?
24. Anti-amyloid drugs: Potential in the treatment of diseases associated with aging
25. C-reactive protein and amyloidosis: From proteins to drugs?
26. β-sheet breaker peptides inhibit fibrollogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
27. Islet amyloid and type 2 diabetes mellitus
28. Gene therapy for diabetes
29. A 48-hour lipid infusion in the rat-time-dependently inhibits glucose-induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation
30. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle
31. Troglitazone prevents mitcohondrial alterations, β-cell destruction, and diabetes in obese prediabetic rats
32. Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vivo
33. Lipotoxicity of β-cells in obesity and in other causes of fatty acid spillover
34. Effects of chronically elevated glucose levels on the functional properties of rat pancreatic β-cells
35. Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes
36. Human pancreatic β-cell DNA-synthesis in islet grafts decreases with increasing organ donor age but increase in response to glucose stimulation in vitro
37. Prolonged exposure of human β-cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation
38. Impaired β-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose
39. Prolonged exposure of human β-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine
40. In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression
41. Long-term effects of aminoguanidine on insulin release and biocynthesis: Evidence that the formation of advanced glycosylation end products inhibits β-cell function
42. Advanced glycation endproducts: A review
43. Regulation of energy metabolism in human cells in aging and diabetes: FoF(1), mtDNA, UCP, and ROS
44. Somatic mutations and aging: A re-evaluation
45. Accelerated telomere shortening and senescence in human pancreatic islet cells stimulated to divide in vitro
46. Stimulated endocrine cell proliferation and differentiation in transplanted human pancreatic islets - Effects of the ob gene and compensatory growth of the implantation organ
47. Telomerase activity is sufficient to allow transformed cells to escape from crisis
48. Growth factor/matrix-induced proliferation of human adult β-cells
49. Effect of homologous placental lactogens, prolactins, and growth hormones on islet β-cell division and insulin secretion in rat, mouse, and human islets: Implication for placental lactogen regulation of islet function during pregnancy
50. β-cell replication in rat pancreatic monolayer cultures. Effects of glucose, tolbutamide, glucocorticoid, growth hormone and glucagon
51. Synthesis of DNA in isolated pancreatic islets maintained in tissue culture
52. Pancreatic β-cell growth and diabetes mellitus
53. The distribution pattern of the pancreatic islet volume in normal and hyperglycaemic mice
54. DNA replication in transplanted and endogenous pancreatic islets of obese-hyperglycemic mice at different stages of the syndrome
55. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles
56. Insulin and multiplication stimulating activity (an insulin-like growth factor) stimulate islet β-cell replication in neonatal rat pancreatic monolayer cultures
57. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?)
58. Adaptation of the endocrine tissue of rat pancreas after partial pancreatectomy - A morphometric study
59. Discordance of exocrine and endocrine growth after 90% pancreatectomy in rats
60. Induction of pancreatic islet neogenesis
61. A novel gene activated in regenerating islets
62. Expression of Reg gene in the Syrian golden hamster pancreatic islet regeneration model
63. Pancreatic β-cell replication and amelioration of surgical diabetes by Reg protein
64. Effect of human placental lactogen on the isolated islets of Langerhans
65. Effects of growth hormone, prolactin, and placental lactogen on insulin content and release, and deoxyribonucleic acid synthesis in cultured pancreatic islets
66. Neonatal rat islet cell cultures synthesize insulin-like growth factor I
67. Effects of platelet-derived growth factor and somatomedin-C/insulin-like growth factor I on the deoxyribonucleic acid replication of fetal rat islets of Langerhans in tissue culture
68. Overexpression of insulin-like growth factor-II in transgenic mice is associated with pancreatic islet cell hyperplasia
69. 3H-thymidine uptake in diabetic and uninephrectomized rats
70. Liver regeneration
71. DNA replication in mouse pancreatic islets transplanted subcapsularly into the kidney or intraportally into the liver
72. Growth of intraportally transplanted islets under liver regeneration stimulus and restoration of normoglycemia in streptozocin-diabetic rats
73. Pancreatic β-cell replication in streptozotocin-diabetic rats: The effect of liver compensatory growth on intraportally engrafted islets
74. Renal growth factors: Past, present and future
75. Progressive pancreatic islet hyperplasia in the islet-targeted, parathyroid hormone-related protein-overexpressing mouse
76. Species differences in susceptibility of transplanted and cultured pancreatic islets to the β-cell toxin alloxan
77. The development and cytodifferentiation of the islets of Langerhans in human embryos and foetuses
78. Embryogenesis of the human pancreatic islets: A light and electron microscopic study
79. Quantitative morphology of endocrine cells in human fetal pancreas
80. Proliferation and differentiation in the human fetal endocrine pancreas
81. The regenerative capacity of the pancreas in duct-ligated rats
82. Epithelial cell proliferation and islet neogenesis in IFN-g transgenic mice
83. β-Cell neogenesis in type 2 diabetes
84. In vitro cultivation of human islets from expanded ductal tissue
85. Control of specific synthesis in the developing pancreas
86. Induction of islet cytodifferentiation by fetal mesenchyme in adult pancreatic ductal epithelium
87. Islet cell neogenesis in the pancreas
88. Differentiation and growth of pancreatic β cells
89. Minireview: The glucagon-like peptides
90. β-Cell differentiation from a human pancreatic cell line in vitro and in vivo
91. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells
92. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats
93. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
94. AC2993 (synthetic exendin-4)
95. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
96. Effect of long-acting GLP-1 derivative NN2211 in 60% pancreatectomised rats
97. Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in rats
98. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
99. Inhibiton of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
100. A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model
101. Use of alternative medicines in diabetes mellitus
102. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat
103. Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given Gymnema sylvestre leaf extracts
104. Effect of a herbomineral preparation D-400 in streptozotocin-induced diabetic rats
105. Pancreatic βb-cell regeneration in rats by (-)-epicatechin
106. Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus